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Abstract
Aims/hypothesis We evaluated the association of QT
interval corrected for heart rate (QTc) and resting heart rate
(rHR) with mortality (all-causes, cardiovascular, cardiac,
and ischaemic heart disease) in subjects with type 1 and
type 2 diabetes.
Methods We followed 523 diabetic patients (221 with type
1 diabetes, 302 with type 2 diabetes) who were recruited
between 1974 and 1977 in Switzerland for the WHO
Multinational Study of Vascular Disease in Diabetes.
Duration of follow-up was 22.6±0.6 years. Causes of death
were obtained from death certificates, hospital records,
post-mortem reports, and additional information given by
treating physicians.
Results In subjects with type 1 diabetes QTc, but not rHR,
was associated with an increased risk of: (1) all-cause
mortality (hazard ratio [HR] 1.10 per 10 ms increase in
QTc, 95% CI 1.02–1.20, p=0.011); (2) mortality due to
cardiovascular (HR 1.15, 1.02–1.31, p=0.024); and (3)
mortality due to cardiac disease (HR 1.19, 1.03–1.36,
p=0.016). Findings for subjects with type 2 diabetes were
different: rHR, but not QTc was associated with mortality
due to: (1) all causes (HR 1.31 per 10 beats per min, 95%
CI 1.15–1.50, p<0.001); (2) cardiovascular disease (HR
1.43, 1.18–1.73, p<0.001); (3) cardiac disease (HR 1.45,
1.19–1.76, p<0.001); and (4) ischaemic heart disease (HR
1.52, 1.21–1.90, p<0.001). Effect modification of QTc by
type 1 and rHR by type 2 diabetes was statistically
significant (p<0.05 for all terms of interaction).
Conclusions/interpretation QTc is associated with long-
term mortality in subjects with type 1 diabetes, whereas
rHR is related to increased mortality risk in subjects with
type 2 diabetes.
Keywords Cardiovascular disease . Diabetes mellitus .
Heart rate .Mortality . QT interval . Risk factors
Abbreviations
bpm beats per min
HR hazard ratio
QTc QT interval corrected for heart rate
rHR resting heart rate
V ventral
Introduction
Compared with the non-diabetic population, subjects with
type 1 and type 2 diabetes mellitus are reported to have an
increase in all-cause mortality [1]. Cardiovascular disease
has been found to be the main reason for this excess
mortality [1–4]. In an effort to identify easily available and
reliable predictors for cardiovascular risk and mortality in
diabetes mellitus, the evaluation of parameters reflecting
myocardial ventricular repolarisation has been of particular
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interest. In subjects with type 1 diabetes, prolongation of
the QT interval corrected for heart rate (QTc) and heart rate
variability have both been shown to be associated with
increased risk of arrhythmia and death, whereas QT
dispersion has been suggested to be less reliable [5].
However, the association between QTc and cardiovascular
mortality in type 2 diabetes is controversial. Some reports
suggest that QTc correlates with an increase in cardiovas-
cular mortality [6–9]. Others have indicated that QT
dispersion might more accurately predict cardiovascular
mortality in this patient group [10–12].
Increased resting heart rate (rHR), which is easily
measurable in clinical practice, has been shown to be an
independent risk factor for cardiovascular death in a non-
diabetic population [13–16]. Recently, rHR has also been
shown to be valuable in estimating the risk of cardiovas-
cular death in patients with type 2 diabetes [8, 10].
However, data directly comparing the role of QTc and
rHR in subjects with type 1 and type 2 diabetes are lacking.
Based on a 23-year follow-up of the Swiss cohort of the
WHO Multinational Study of Vascular Disease in Diabetes
[17], the present study aimed to evaluate the long-term
association of QTc and rHR with mortality in patients with
type 1 and type 2 diabetes within the same study
framework.
Subjects and methods
Study population The WHO Multinational Study of Vascu-
lar Disease in Diabetes is a multicentre international study
with a central protocol applied by 14 centres in 13 countries
[18]. For the original study, each centre recruited stratified
samples of 250 men and 250 women with a clinical
diagnosis of diabetes, aged between 35 and 54 years at
time of recruitment. The present analysis was based on the
Swiss cohort of this study [17], which included 533
subjects randomly selected according to the central protocol
by 231 local practitioners [17, 18]. The sample was
representative of a large area including almost the entire
country. The diagnosis of diabetes mellitus was made on a
clinical basis. Subjects were eligible if diabetes had been
diagnosed at least 1 year prior to study entry and anti-
diabetic treatment (diet, oral glucose-lowering drugs,
insulin) had been initiated by their physicians. If insulin
was needed for treatment within 1 year of diagnosis,
subjects were considered to have type 1 diabetes [18], the
remaining subjects were classified as having type 2
diabetes. These comparably simple clinical definitions with
acknowledged inadequacies were used because of the
constraints on information available and the need for
consistency with earlier reports [19–21]. At baseline, a
standardised clinical examination was performed, including
a detailed questionnaire with information on diabetes
diagnosis, the duration and treatment, as well as on
symptoms of vascular and cardiac disease. Previous
medical history also included the use of other medication
(including diuretics, lipid-lowering drugs and blood pres-
sure-lowering drugs). Central randomisation to the cohort
was stratified according to sex, age (35–41 years, 42–
48 years, 49–54 years) and duration of diabetes (1–6 years,
7–13 years, 14 years and more). In addition, height and
weight were recorded, and blood pressure was measured
after 30 min of rest; hypertension being defined as a
systolic blood pressure of ≥160 mmHg, and/or a diastolic
blood pressure ≥95 mmHg, and/or the use of antihyperten-
sive medication including diuretics. Urine was tested
semiquantitatively for proteinuria using the salicylsulfonic
acid method, blood samples were drawn to measure fasting
plasma glucose, cholesterol, triacylglycerol and creatinine,
and a 12-lead ECG was recorded. These baseline inves-
tigations were carried out between February 1974 and May
1977. All subjects gave informed consent. Analyses were
carried out in accordance with the Declaration of Helsinki
and the Swiss laws regarding data security. Data used were
made fully anonymous before the analyses.
ECG recordings Standard 12-lead resting ECGs were
recorded with the patient supine and resting for at least
30 min. Analyses were performed according to the
Minnesota code [22]. All tracings were evaluated by the
same two experienced readers. The following items were
derived from the ECG code results: ‘ECG coronary
probable’ consisting of code 1.1, 1.2 and 7.1; ‘ECG
coronary possible’ consisting of codes 1.3, 4.1, 4.2, 4.3,
5.1, 5.2 and 5.3; all other recordings were rated as ‘ECG
coronary unlikely’ [22]. QT and RR intervals were
measured by an experienced cardiologist, blinded to the
diagnosis and outcome of the individual patients. QT
interval length was usually measured in the ventral (V)2
and V3 leads using a digitiser (CalComp, Newbury, Berks,
UK). Measurements in V2 and V3 were chosen, since they
provide a close approximation of maximal QT [23]. QT
interval length was measured from the onset of the QRS to
the end of the T wave. In the presence of U waves, the end
of the QT interval was set at the nadir of the curve between
T and U wave. Maximal QT interval was corrected for the
respective heart rate using the Bazett formula [24]
QTcBazett ¼ QT

RR1=2
 
. In addition, the formulas sug-
gested by Fridericia QTcFridericia¼QT

RR1=3
 
[25] and the
Framingham formula derived by linear regression
QTc Sagie¼ QTþ 0:154 1 RRð Þ
 
were used [26].
Follow-up and outcome definition The status (alive/dead)
and date of death of each subject were ascertained as per 1
January 1998 on the basis of data obtained from population
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registries. In deceased patients, the underlying cause of
each death was determined from a copy of the death
certificate, hospital records, post-mortem reports (where
available), and additional information given by the treating
physicians. Causes of death were coded according to the
International Classification of Disease (ICD-9). Cardiovas-
cular mortality included codes 390 to 459 and 798.1,
cardiac mortality codes 390 to 429 and 798.1, and mortality
due to ischaemic heart disease codes 410 to 414.
Statistical analysis Statistical assessment of potential dif-
ferences in baseline characteristics between patients with
type 1 and type 2 diabetes mellitus was carried out using
the two-tailed unpaired Student’s t test for continuous
variables and the Pearson’s chi-squared test for proportions.
The impact of QTc interval and rHR on mortality rates was
assessed by time-to-event analysis using Cox proportional
hazards models. Date of last clinical contact or documented
date of leaving Switzerland was used for censored subjects,
and exact date of death for subjects who had died. Analyses
were conducted separately for subjects with type 1 and type
2 diabetes respectively, regarding all-cause, cardiovascular
and cardiac mortality, and death due to ischaemic heart
disease. Univariable analyses were performed before
adjusting the regression model for age and sex. Then a
‘full model’ was fitted including the following explanatory
variables: age, sex, BMI, duration of diabetes, total
cholesterol, triacylglycerol, fasting plasma glucose, pres-
ence of hypertension/antihypertensive medication, history
of coronary heart disease, history of microvascular disease,
smoking, alcohol consumption, treatment with insulin
(subjects with type 2 diabetes) and treatment with diuretics.
QTc was included in the analysis of rHR and vice versa.
The model’s assumptions (proportionality) were regularly
checked. Analyses were then repeated using cut-off values
corresponding to the lower limits of the upper quartiles
(QTc interval ≥450 ms or <450 ms in type 1, rHR ≥90 beats
per min [bpm] or <90 bpm in type 2 diabetes). Comparable
cut-off values have been suggested in earlier reports [13,
27, 28]. Based on these cut-off values, Kaplan–Meier
survival analyses were performed for the main endpoint
(overall mortality) and differences were statistically
assessed using log-rank test. To formally assess effect
modification of QTc and rHR by diabetes type a confirma-
tory analysis was performed including terms of interaction
in an analysis by Cox regression. Finally, regression models
using the Bazett formula for QTc were compared with
models using the formula suggested by Fridericia [25] and
by Sagie [26]. All analyses were performed using Stata
version 8.2 (Stata Corporation, College Station, TX, USA).
Results are given as mean±SD and as hazard ratio (HR)
with 95% CI. p values <0.05 were considered statistically
significant.
Results
Study characteristics The entire cohort comprised 533
patients and baseline ECGs were available in 523 patients
(221 type 1 diabetes, 302 type 2 diabetes). During follow-
up 18 patients left the country and were censored
accordingly. This translated into a drop-out rate of 3.4%.
Baseline ECG was normal in more than three-quarters of all
patients (85% and 77% for types 1 and 2 diabetes,
respectively). The mean difference of repeated determina-
tions of QTc was 2.8%. Mean follow-up was 22.6±0.6 years
corresponding to a total of 11,815 person-years. Baseline
characteristics are shown in Table 1. The proportion of
women in the type 1 diabetes group was 54%, that for type
2 diabetes was lower (44%). Overall there were slightly
more men than women (278, 255). Subjects with type 1
diabetes were generally younger, but had a longer duration
of diabetes and a higher prevalence of retinopathy as well
as higher mean values for fasting glucose at baseline. In
contrast, subjects with type 2 diabetes showed higher
values for BMI, blood pressure, and lipids, with coronary
heart disease reported more frequently. Only a minority of
subjects with type 2 diabetes were being treated with diet
alone; two-thirds were using oral glucose-lowering drugs
(e.g. sulfonylureas and/or biguanides), and less than one-
third were being treated with insulin. In contrast, all
patients with type 1 diabetes used insulin, with a minority
also receiving oral glucose-lowering drugs (e.g. bigua-
nides). While the proportion of subjects treated with
antihypertensive drugs other than diuretics as well as with
lipid-lowering drugs was comparable for the two types of
diabetes, the use of diuretics was more frequent in subjects
with type 2 diabetes. At baseline rHR tended to be higher
and QTc interval was significantly longer in patients with
type 1 diabetes than in those with type 2 diabetes.
All-cause mortality During the study period 107 subjects
with type 1 diabetes and 158 subjects with type 2 diabetes
died. In subjects with type 1 diabetes, QTc was positively
associated with overall mortality. The unadjusted HR
was 1.07 per 10 ms increase of QTc (95% CI 1.01–1.15,
p=0.033). This was not substantially altered when the
model was adjusted for age and sex (HR 1.10, 95% 1.02–
1.18, p=0.009). The association persisted after additional
inclusion of further explanatory variables as stated in
Subjects and methods (‘full model’, HR 1.10, 1.02–1.20,
p=0.011). In contrast, no association of rHR with this
endpoint was detected in type 1 diabetes (p=0.924) (Fig. 1,
Tables 2 and 3). Subjects with type 2 diabetes revealed a
strong positive association between rHR and mortality due
to all causes. The unadjusted HR was 1.27 per 10 bpm
(95% CI 1.14–1.41, p<0.001). Again, adjustment for age
and sex revealed a similar HR (1.28, 1.16–1.42, p<0.001),
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which was not substantially altered in the fully adjusted
model (HR 1.31, 1.15–1.50, p<0.001). A comparable effect
was not detected for QTc in these patients (p=0.380). The
analysis of an effect modification of QTc and rHR by
diabetes type revealed a statistically significant association
between QTc and type 1 diabetes and between rHR and
type 2 diabetes (p=0.026 and p=0.014 for terms of
interaction; Fig. 1), thereby underscoring the differences
between the two types of diabetes. Subjects with type 1
diabetes and a QTc ≥450 ms had a twofold increased
mortality risk compared with those with a QTc <450 ms
(HR 2.04, 95% CI 1.27–3.25, p=0.003). In type 2 diabetes,
a comparable increase in risk was observed when subjects
with a rHR ≥90 bpm were compared with those with rHR
<90 bpm (HR 2.23, 95% CI 1.43–3.46, p<0.001). Results
of Kaplan–Meier survival analysis are shown in Fig. 2
(p values for log-rank test 0.019 and 0.001 for type 1 and
type 2 diabetes, respectively).
Cardiovascular mortality In 50 subjects with type 1 and in
76 subjects with type 2 diabetes, death was classified as due
to cardiovascular disease. As for all-cause mortality, QTc
but not rHR was positively associated with cardiovascular
mortality in type 1 diabetes (Fig. 1, Table 2). HRs for QTc
tended to be lower in the unadjusted model and after
inclusion of age and sex when compared with the fully
adjusted model, although conventional levels of signifi-
cance were reached only in the latter (Table 3). Inverse
findings were observed in subjects with type 2 diabetes,
where rHR but not QTc was related to this endpoint (Fig. 1,
Table 2). Again, the HR in the unadjusted model was
similar to those after adjustment for age and sex and to the
‘full model’ (Table 3). Confirmatory analysis using inter-
action terms revealed that the differences between the
two types of diabetes were unlikely to be a chance finding
(p=0.008 and p=0.008 for interaction, respectively; Fig. 1).
In type 1 diabetes, mortality risk for a QTc ≥450 ms was
again increased twofold compared with a QTc <450 ms (HR
2.34, 95% CI 1.16–4.71, p=0.018). In type 2 diabetes a
rHR ≥90 bpm was even associated with a threefold
increased risk (HR 3.27, 95% CI 1.76–6.09, p<0.001).
Cardiac mortality Cardiac mortality was confirmed in 43
type 1 and 71 type 2 diabetic patients. In the former, QTc
Table 1 Study characteristics
Data are mean values±SD
QTc QT interval corrected for
heart rate according to the
formula suggested by Bazett
*Diuretics excluded
a p<0.05 for difference between
type 1 and type 2 diabetes
b p<0.001 for difference be-
tween type 1 and type 2
Type 1 diabetes Type 2 diabetes
Demographic
Total number of patients (n) 225 308
Age (years) 43±6 46±6b
Female patients (n) 121 (54%) 134 (44%)a
Clinical
BMI (kg/m2) 24±4 28±5b
Duration of diabetes (years) 15±10 9±6b
Systolic blood pressure (mmHg) 136±20 141±21a
Diastolic blood pressure (mmHg) 86±11 89±11b
Nicotine consumption (no. cigarettes per day) 4±8 4±8
Alcohol consumption (g/day) 8±17 12±28
ECG performed 221 (98%) 302 (98%)
ECG normal 187 (85%) 234 (77%)
Resting heart rate (bpm) 79±13 77±14
QTc (ms) 433±30 426±32a
Biochemical
Total cholesterol (mmol/l) 6.1±1.4 6.5±1.4a
Triacylglycerol (mmol/l) 1.4±1.2 2.4±2.7b
Fasting glucose (mmol/l) 11.7±6.5 10±4.1b
Serum creatinine (μmol/l) 91.9±43.3 86.6±27.4
Micro- and macrovascular disease
Presence of retinopathy 117 (52%) 68 (22%)b
Presence of proteinuria 51 (23%) 75 (24%)
Presence of coronary heart disease 45 (20%) 96 (31%)a
Medication
Diet alone as glucose-lowering treatment 0 (0%) 27 (9%)b
Use of oral glucose-lowering drugs 27 (12%) 188 (62%)b
Use of insulin 225 (100%) 90 (29%)b
Use of any antihypertensive drug* 33 (15%) 68 (22%)
Use of lipid-lowering drugs 4 (2%) 15 (5%)
Use of diuretics 22 (10%) 60 (20%)a
Diabetologia (2007) 50:186–194 189
but not rHR was significantly associated with cardiac
mortality (Fig. 1, Table 2). HRs tended to be slightly
higher in the fully adjusted model compared with the
unadjusted analysis (Table 3). In type 2 diabetes, rHR was
found to predict cardiac mortality, whereas QTc was not
(Fig. 1, Table 2). Adjustment for age and sex and inclusion
of further explanatory variables did not affect HRs (Table 3).
Again, effect modification showed that QTc was related to
type 1 and rHR to type 2 diabetes (p=0.006 and p=0.009
for interaction, respectively; Fig. 1). HR for subjects with
type 1 diabetes and QTc ≥450 ms was 2.90 (95% CI 1.36–
6.16, p=0.006). In subjects with type 2 diabetes, risk of
cardiac mortality was comparably increased for those with a
rHR ≥90 bpm (HR 3.51, 95% CI 1.86–6.64, p<0.001).
Death due to ischaemic heart disease There were 25 and
52 deaths due to ischaemic heart disease in subjects with
type 1 and type 2 diabetes, respectively. In the former, no
statistically significant association was found for either QTc
nor rHR (Fig. 1, Tables 2 and 3). In subjects with type 2
diabetes, a strong positive association persisted for rHR but
not for QTc (p=0.010 for interaction; Fig. 1, Tables 2 and 3).
Type 2 diabetic subjects with a rHR of ≥90 bpm had a more
than threefold increased risk of dying from ischaemic heart
disease (HR 3.33, 95% CI 1.63–6.77, p=0.001).
Different formulas for correcting QT interval for heart
rate Similar results were obtained using the formulas
proposed by Fridericia [25] or Sagie [26] when compared
with Bazett’s formula [24]. For example, in subjects with
type 1 diabetes, HR for all-cause mortality was 1.10 using
Bazett’s model. Applying Fridericia’s or Sagie’s approach
the corresponding values were 1.12 and 1.13, respectively
(Table 2). The same additional explanatory variables were
used for all three analyses. The current literature is mainly
based on Bazett’s formula. In order to compare the present
findings with previous reports, the formula suggested by
Bazett was included in the final model.
Discussion
The main finding of this 23-year follow-up was a difference
in the prognostic value of rHR and QTc between the two
types of diabetes. In subjects with type 1 diabetes QTc, but
not rHR was associated with an increased risk of all-cause
mortality and mortality due to cardiovascular and cardiac
disease. In contrast, in type 2 diabetes rHR, but not QTc
was consistently related to mortality due to all causes,
cardiovascular, cardiac, and ischaemic heart disease. Inter-
estingly, in type 1 diabetes a QTc interval ≥450 ms
translated into a twofold increase in all-cause mortality
and a threefold increase in cardiac mortality. In subjects
with type 2 diabetes a comparable increase in mortality risk
was found for a rHR of ≥90 bpm compared with a rHR
<90 bpm.
To our knowledge, this is the first study to prospectively
assess the role of QTc and rHR in both types of diabetes
within the same study framework. Its findings confirm the
prognostic value of QTc as an independent risk factor for
all-cause mortality in type 1 diabetes [5, 28–30]. In
addition to the results of Rossing et al. [5], the present
QTc interval Resting heart rate
0.6
0.8
1.0
1.2
1.4
1.6
1.8
All-cause Cardiovascular Cardiac Ischaemic heart
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Fig. 1 Hazard ratios for
mortality due to all causes,
cardiovascular disease, cardiac
disease, and ischaemic heart
disease per incremental 10 ms
prolongation of QTc interval and
per 10 bpm increase in resting
heart rate, respectively. p values
are for effect modification
by type of diabetes (closed
circles, type 1 diabetes; open
circles, type 2 diabetes)
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analysis found QTc to be associated not only with overall
mortality but also with cardiovascular and cardiac mortality.
Moreover, it also reproduced the findings of Sawicki and
colleagues, which were made in subjects with nephropathy
[28] in a more general sample of subjects with type 1
diabetes. The HR for overall mortality found in the present
analysis was comparable to that in Rossing’s report [5], but
tended to be lower than the risk ratio found in subjects with
overt nephropathy [28] (1.10 and 1.47 per 10 ms, respec-
tively). Earlier reports have suggested that the association
between QTc and cardiovascular disease was stronger in
male than in female subjects with type 1 diabetes [30]. The
present study had slightly more female subjects in the
group with type 1 diabetes, thereby potentially under-
estimating the prognostic value of QTc for this patient
group.
An increased rHR has been found to be related to all-
cause mortality and cardiovascular death in several trials of
non-diabetic subjects [13, 31–34], and in subjects with type
2 diabetes [8, 10]. Our analysis confirmed the role of rHR
as an easily measurable factor for risk assessment of all-
cause and cardiovascular mortality in subjects with type 2
diabetes, and had comparable HRs. In addition to findings
of previous reports, we also observed a relation between
elevated rHR and both cardiac mortality and mortality due
to ischaemic heart disease. On the other hand, the present
analysis did not confirm an association between QTc and
any of the endpoints in type 2 diabetes as has been reported
previously [6, 7, 9, 10, 35]. Given previous hypotheses that
prolongation of QTc as a marker of cardiac autonomic
neuropathy could be of greater importance in type 1 than in
type 2 diabetes [5], our findings on this count are
intriguing, and it can only be speculated on the underlying
mechanisms.
In subjects with type 1 diabetes an increased prevalence
of prolonged QTc has been reported before [30, 36], in
particular in subjects with autonomic neuropathy [36–38].
This may indicate that increased QTc relates to diabetic
autonomic neuropathy [39]. QTc prolongation has been
suggested to result from a reduction in vagal activity and an
Table 2 Hazard ratios (95% CI) for mortality due to all causes, cardiovascular, cardiac, and ischaemic heart disease
Type 1 diabetes Type 2 diabetes
All-cause mortality
QTc Bazett (model with rHR) 1.10 (1.02–1.20) p=0.011 0.97 (0.91–1.03) p=0.380
rHR (model with QTc Bazett) 0.98 (0.83–1.18) p=0.924 1.31 (1.15–1.50) p<0.001
QTc Fridericia (model with rHR) 1.12 (1.03–1.21) p=0.011 0.97 (0.91–1.03) p=0.343
rHR (model with QTc Fridericia) 1.09 (0.93–1.28) p=0.307 1.28 (1.13–1.46) p<0.001
QTc Sagie (model with rHR) 1.13 (1.03–1.23) p=0.012 0.97 (0.90–1.04) p=0.366
rHR (model with QTc Sagie) 1.10 (0.94–1.30) p=0.241 1.28 (1.13–1.46) p<0.001
Cardiovascular mortality
QTc Bazett (model with rHR) 1.15 (1.02–1.31) p=0.024 0.94 (0.85–1.03) p=0.160
rHR (model with QTc Bazett) 0.99 (0.77–1.27) p=0.917 1.43 (1.18–1.73) p<0.001
QTc Fridericia (model with rHR) 1.16 (1.02–1.32) p=0.026 0.93 (0.84–1.02) p=0.140
rHR (model with QTc Fridericia) 1.12 (0.88–1.42) p=0.346 1.35 (1.12–1.63) p=0.002
QTc Sagie (model with rHR) 1.18 (1.02–1.36) p=0.023 0.91 (0.82–1.02) p=0.100
rHR (model with QTc Sagie) 1.14 (0.90–1.46) p=0.272 1.34 (1.11–1.61) p=0.002
Cardiac mortality
QTc Bazett (model with rHR) 1.19 (1.03–1.36) p=0.016 0.94 (0.85–1.03) p=0.182
rHR (model with QTc Bazett) 0.98 (0.74–1.28) p=0.865 1.45 (1.19–1.76) p<0.001
QTc Fridericia (model with rHR) 1.19 (1.03–1.38) p=0.018 0.93 (0.84–1.03) p=0.163
rHR (model with QTc Fridericia) 1.13 (0.88–1.46) p=0.336 1.37 (1.13–1.66) p=0.001
QTc Sagie (model with rHR) 1.21 (1.03–1.42) p=0.017 0.92 (0.82–1.02) p=0.115
rHR (model with QTc Sagie) 1.16 (0.90–1.51) p=0.256 1.36 (1.12–1.66) p=0.002
Death due to ischaemic heart disease
QTc Bazett (model with rHR) 1.08 (0.90–1.30) p=0.397 0.97 (0.87–1.09) p=0.617
rHR (model with QTc Bazett) 0.91 (0.58–1.42) p=0.678 1.52 (1.21–1.90) p<0.001
QTc Fridericia (model with rHR) 1.09 (0.90–1.32) p=0.399 0.97 (0.86–1.09) p=0.581
rHR (model with QTc Fridericia) 0.98 (0.64–1.49) p=0.914 1.48 (1.18–1.85) p=0.001
QTc Sagie (model with rHR) 1.09 (0.89–1.34) p=0.401 0.96 (0.84–1.09) p=0.531
rHR (model with QTc Sagie) 0.99 (0.64–1.51) p=0.946 1.47 (1.18–1.84) p=0.001
Data are given per incremental 10 ms prolongation of QTc interval and 10 bpm increase in rHR, respectively Formulas for calculation of QTc:
Bazett [24], Fridericia [25], Sagie [26], as indicated by subscript All models adjusted for age, sex, BMI, duration of diabetes, total
cholesterol, triacylglycerol, fasting plasma glucose, presence of hypertension, history of coronary heart disease, history of microvascular
disease, smoking, alcohol consumption, treatment with insulin (subjects with type 2 diabetes) and treatment with diuretics.
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increased sympathetic tonus, thereby reflecting myocardial
autonomic instability and an increased risk of arrhythmia
and cardiac death [9, 28, 36, 40]. Compared with previous
publications reporting an association of QTc with mortality
in type 2 diabetes [9, 10, 35], subjects with type 2 diabetes
were substantially younger in the present study. It should
also be noted that some earlier reports revealing an
association between QTc and mortality were cross-sectional
[35] or based on a case–control design [9] and in the case of
prospective trials [6, 7, 10] had a considerably shorter
follow-up.
In type 2 diabetes hyperglycaemia is often associated
with a pro-inflammatory state including obesity, dyslipi-
daemia and hypertension, thereby promoting the develop-
ment of atherosclerosis [41]. Interestingly, impaired
myocardial oxygen supply has also been shown to
influence QT interval [28, 30]. As has been pointed out
before [6, 10], QTc is possibly a composite marker,
reflecting abnormal ventricular repolarisation due to ischae-
mia, fibrosis, left ventricular hypertrophy and dilatation,
autonomic neuropathy, and vascular damage, conditions
frequently present in diabetic myocardium. Although the
models used in this analysis were adjusted for the pre-
existence of coronary heart disease, we could not fully rule
out a potential interference due to silent heart disease in
subjects with diabetes, since invasive cardiac procedures
were not performed.
The strength of the present study lies in the long follow-
up period, the well-defined cohort of diabetic subjects
(Swiss cohort [17] of the WHO Multinational Study of
Vascular Disease in Diabetes [18, 22]), the evaluation of
pre-specified endpoints, and the small drop-out rate.
Considerable efforts were undertaken to adjust for relevant
factors known to affect cardiovascular risk and/or myocar-
Table 3 Hazard ratios (95% CI) for mortality due to all causes, and to cardiovascular, cardiac and ischaemic heart disease
All-cause
mortality
Cardiovascular
mortality
Cardiac
mortality
Death due to ischaemic
heart disease
Type 1 diabetes
QTc Crude/unadjusted 1.07
(1.01–1.15)
p=0.033 1.08
(0.99–1.19)
p=0.098 1.10
(0.99–1.22)
p=0.084 1.04
(0.91–1.19)
p=0.610
Adjusted for age
and sex
1.10
(1.02–1.18)
p=0.009 1.10
(1.00–1.22)
p=0.057 1.12
(1.00–1.25)
p=0.055 1.06
(0.92–1.23)
p=0.410
Full model* 1.10
(1.02–1.20)
p=0.011 1.15
(1.02–1.31)
p=0.024 1.19
(1.03–1.36)
p=0.016 1.08
(0.90–1.30)
p=0.397
Type 2 diabetes
rHR Crude/unadjusted 1.27
(1.14–1.41)
p<0.001 1.35
(1.15–1.57)
p<0.001 1.36
(1.16–1.60)
p<0.001 1.42
(1.18–1.70)
p<0.001
Adjusted for age
and sex
1.28
(1.16–1.42)
p<0.001 1.36
(1.18–1.57)
p<0.001 1.37
(1.18–1.59)
p<0.001 1.41
(1.19–1.68)
p<0.001
Full model* 1.31
(1.15–1.50)
p<0.001 1.43
(1.18–1.73)
p<0.001 1.45
(1.19–1.76)
p<0.001 1.52
(1.21–1.90)
p<0.001
Results are shown from a three-step approach in regression modelling (unadjusted, adjusted for age and sex, and ‘full model’). Data are given per
incremental 10 ms prolongation of QTc interval for type 1 and 10 bpm increase in rHR for type 2 diabetes, respectively.
*Full model adjusted for: age, sex, BMI, diabetes duration; levels of fasting glucose, triacylglycerol and cholesterol; presence or absence of
microvascular disease, hypertension, coronary heart disease; treatment with diuretics, insulin (for type 2 diabetes); alcohol consumption,
smoking. QTc was included in the analysis of rHR and vice versa.
Fig. 2 Kaplan–Meier estimation
of survival probabilities for over-
all mortality. a The survival
probabilities for type 1 diabetes,
comparing patients with a QTc
interval ≥450 ms (solid line) with
those with a QTc interval
<450 ms (dotted line). p=0.019
for difference by log-rank test.
b Survival probabilities for type 2
diabetes comparing patients with
a resting heart rate ≥90 bpm
(solid line) with those with rHR
<90 bpm (dotted line). p=0.001
for difference by log-rank test
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dial ventricular repolarisation This allowed inclusion of
parameters that earlier reports had not been adjusted for,
despite their known influence on mortality (e.g. alcohol
consumption) [42]. Moreover, as the use of Bazett’s
formula [24] to calculate QTc has been questioned before
[8, 26, 43], possible differences in effect were taken into
account by performing sensitivity analyses using the
formulas suggested by Fridericia [25] and by Sagie [26].
In contrast to earlier reports [8], inclusion of different
calculations of QTc did not substantially alter our results
(Table 2). As a consequence, Bazett’s formula was included
in the final model to allow for comparisons with other
reports.
Nevertheless, we must acknowledge some limitations to
our findings. Thus rHR was determined from ECG record-
ings, whereas in clinical practice it is usually measured by
pulse palpation, rendering it subject to variation due to
circumstantial factors (medical setting, circadian rhythm,
body position etc.). In addition, QTc and rHR can
potentially be influenced by specific medication. Although
the use of antihypertensive medication and diuretics was
recorded in the present trial, data did not allow to
specifically adjust for the use of beta blockers. Since it is
known that treatment with these agents can influence both
QTc [44], and rHR, a potential interfering effect on the
present findings cannot be fully excluded. It should,
however, be noted that at the time of study entry only a
limited number of beta blockers was available in Switzer-
land. Moreover, in another study [9] adjustment for use of
beta blockers only modestly attenuated the association
between QTc and the risk of primary cardiac arrest. Another
known factor to influence rHR is physical training [45].
Tachycardia may be a marker of decreased physical fitness,
which in turn may be associated with an increased risk of
mortality [46]. Interestingly, increased rHR was found to be
an independent prognostic factor of cardiovascular mortal-
ity in studies controlling for energy expenditure as an
indicator of physical fitness [31].
In deceased patients, the underlying cause of death was
determined from a copy of the death certificate, hospital
records, post-mortem reports, and additional information
given by the treating physicians. Despite intensive efforts to
collect comprehensive data, the cause of death may, in
some cases, have been misclassified, especially if based
only on death certificates, which are a comparatively
unreliable source of information. Thus, our findings
regarding all-cause mortality are clearly more robust than
those for cause-specific mortality.
Glycaemic control has been shown to be related to
macrovascular complications [47, 48], and was, therefore,
included in the present analysis. Importantly, information
on glycaemic control had to be based on fasting glucose,
since HbA1c was not available at the time of study entry,
thereby potentially limiting the accuracy of adjustment.
With regard to this, however, Veglio et al. did not report a
significant influence of HbA1c levels on QTc [35].
In summary, this study, performed in a large, diabetic
cohort followed over 23 years, confirms that in subjects
with type 1 diabetes prolonged QTc is associated with an
increased mortality risk due to all causes, and to cardio-
vascular and cardiac disease, whereas no association was
found for rHR. In contrast, in subjects with type 2 diabetes,
elevated rHR, but not QTc, is associated with an increased
risk of all-cause mortality as well as risk of death due to
cardiovascular, cardiac and ischaemic heart disease. The
underlying pathophysiological mechanisms are probably
complex and remain to be fully elucidated.
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